cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.29950543.v1
title: Association of lactate-albumin ratio with native liver survival in paediatric acute liver failure: a 10-year retrospective study

description: Paediatric acute liver failure (PALF) is a severe life-threatening condition with complex aetiologies and high mortality rates. Prognostic research, particularly in the Chinese paediatric population, is limited. The lactate-albumin ratio (LAR) is a potential prognostic indicator for adverse outcomes in critical illness, and its correlation with survival with the native liver (SNL) in PALF patients requires further study. LAR was calculated as follows: [lactate (mmol/L)/serum albumin (g/L)×100%]. This study utilized early LAR, defined as the initial measurement of lactate and albumin levels conducted within the first 24h following hospital admission, to investigate the correlation between LAR and SNL in PALF. This retrospective cohort study included 77 patients with PALF. The data collected included demographic information, etiologies, complications, laboratory findings, and the Liver Injury Unit score. Logistic regression, smooth curve fitting, generalized additive models, and interaction effects analysis were used for statistical analysis. Among 77 patients, 46.8% (36 cases) had SNL, with 14.3% (11 cases) requiring transplantation. A significant decrease in SNL was associated with higher LAR (<i>p</i> = 0.005), with a 4% decline in SNL for each 1% increase in LAR. When the LAR≥ 10.5%, the odds ratios(ORs) for SNL in Models I, II, and III were 0.259 (95% confidence interval(CI) 0.101-0.668), 0.213 (95% CI 0.076-0.6), and 0.053 (95% CI 0.007-0.378), respectively. Smooth curve fitting confirmed a linear relationship (<i>p</i> for nonlinearity = 0.531). The subgroup analysis showed an association between LAR and SNL in non-shocked patients (OR 0.1121, 95% CI 0.0153-0.8206) and significant interactions in patients with higher-grade hepatic encephalopathy (<i>p</i> &lt; 0.001). No significant differences in clinical outcomes were observed regardless of etiology. Our findings suggest a significant correlation between LAR and SNL in patients with PALF from Northeast China. Elevated LAR is predictive of a reduced probability of surviving PALF without the need for liver transplantation, highlighting its potential as a prognostic marker in PALF.
DOI: 10.6084/m9.figshare.30327326
title: Effectiveness of metabolic management centers online tools in patients with type 2 diabetes

description: To assess the value of National Metabolic Management Centers (MMC) specialized online tools, for the maintenance of metabolic control among patients with type 2 diabetes (T2DM). This retrospective study enrolled T2DM patients from 10 MMCs (June 2017–April 2021) and divided into non- and application of online tools (non-AOT and AOT) groups. Propensity score matching (PSM) was used to balance the characteristics of patients between groups. The effect of online tools was evaluated by the change in HbA1c, with additional stratified analyses in subgroups. After PSM, 12528 patients with T2DM were followed for a median of 15.88 (7.10, 24.27) months, the AOT group demonstrated better control of HbA1c (−0.90 [−2.60, 0.00] % vs. −0.70 [−2.20, 0.10] %, <i>p</i> &lt; 0.0001), and a greater reduction in body mass index (−0.34 ± 1.68 kg/m<sup>2</sup> vs. −0.13 ± 1.55 kg/m<sup>2</sup>, <i>p</i> &lt; 0.0001) and Visceral fat area (VFA) (−5.33 ± 30.95 cm<sup>2</sup> vs. −3.97 ± 26.11 cm<sup>2</sup>, <i>p</i> = 0.009), compared to the non-AOT group, and the high-frequency AOT group achieved a more significant HbA1c reduction than the low-frequency AOT group (−1.50 [−3.60, −0.30] % vs. −0.80 [−2.38, 0.10] %, <i>p</i> &lt; 0.0001) and a greater reduction in VFA (−7.07 ± 30.32 cm<sup>2</sup> vs. −4.90 ± 31.10 cm<sup>2</sup>, <i>p</i> = 0.010) after adjustment. Stratification analyses revealed greater HbA1c reductions in those with younger age, lower education level or poor HbA1c control at baseline. MMC online tools significantly improve metabolic outcomes, particularly for T2DM patients with younger age, lower education levels or poor baseline HbA1c control. They offer a scalable and effective model for out-of-hospital diabetes care.
DOI: 10.6084/m9.figshare.30327326.v1
title: Effectiveness of metabolic management centers online tools in patients with type 2 diabetes

description: To assess the value of National Metabolic Management Centers (MMC) specialized online tools, for the maintenance of metabolic control among patients with type 2 diabetes (T2DM). This retrospective study enrolled T2DM patients from 10 MMCs (June 2017–April 2021) and divided into non- and application of online tools (non-AOT and AOT) groups. Propensity score matching (PSM) was used to balance the characteristics of patients between groups. The effect of online tools was evaluated by the change in HbA1c, with additional stratified analyses in subgroups. After PSM, 12528 patients with T2DM were followed for a median of 15.88 (7.10, 24.27) months, the AOT group demonstrated better control of HbA1c (−0.90 [−2.60, 0.00] % vs. −0.70 [−2.20, 0.10] %, <i>p</i> &lt; 0.0001), and a greater reduction in body mass index (−0.34 ± 1.68 kg/m<sup>2</sup> vs. −0.13 ± 1.55 kg/m<sup>2</sup>, <i>p</i> &lt; 0.0001) and Visceral fat area (VFA) (−5.33 ± 30.95 cm<sup>2</sup> vs. −3.97 ± 26.11 cm<sup>2</sup>, <i>p</i> = 0.009), compared to the non-AOT group, and the high-frequency AOT group achieved a more significant HbA1c reduction than the low-frequency AOT group (−1.50 [−3.60, −0.30] % vs. −0.80 [−2.38, 0.10] %, <i>p</i> &lt; 0.0001) and a greater reduction in VFA (−7.07 ± 30.32 cm<sup>2</sup> vs. −4.90 ± 31.10 cm<sup>2</sup>, <i>p</i> = 0.010) after adjustment. Stratification analyses revealed greater HbA1c reductions in those with younger age, lower education level or poor HbA1c control at baseline. MMC online tools significantly improve metabolic outcomes, particularly for T2DM patients with younger age, lower education levels or poor baseline HbA1c control. They offer a scalable and effective model for out-of-hospital diabetes care.
DOI: 10.6084/m9.figshare.29948734
title: B blood type indicates poorer overall survival in patients with severe burn injuries: a case-control study

description: This study focuses on the prognostic impact of ABO blood type in patients with severe burn injuries, particularly following the Kunshan explosion, exploring an under-investigated area of burn injury outcomes. Data from patients admitted after the Kunshan explosion were analyzed, using chi-square tests and multivariate Cox regression to investigate the relationship between ABO blood type and overall survival (OS). The study utilized various performance metrics, including the receiver operator characteristic curve (ROC), decision curve analysis (DCA) and Kaplan-Meier survival curve, for model assessment, along with a subgroup analysis for associated factors. The research identified ABO blood type as an independent prognostic factor in severe burn injuries. It was found that blood type O is associated with better OS, while blood type B is linked to lower OS (<i>p</i> = 0.001). Clinical variables such as acute kidney injury (AKI), sepsis, and other complications influenced the effect of ABO blood type on OS, according to our subgroup analysis. Our findings indicated that blood type B was an independent and significant predictor of OS in patients with severe burn injuries, likely due to differences in immune and coagulation responses. Although the study focused on the relationship between blood type and OS, it also highlighted the importance of other factors, such as patient comorbidities and treatment approaches.
DOI: 10.6084/m9.figshare.29948734.v1
title: B blood type indicates poorer overall survival in patients with severe burn injuries: a case-control study

description: This study focuses on the prognostic impact of ABO blood type in patients with severe burn injuries, particularly following the Kunshan explosion, exploring an under-investigated area of burn injury outcomes. Data from patients admitted after the Kunshan explosion were analyzed, using chi-square tests and multivariate Cox regression to investigate the relationship between ABO blood type and overall survival (OS). The study utilized various performance metrics, including the receiver operator characteristic curve (ROC), decision curve analysis (DCA) and Kaplan-Meier survival curve, for model assessment, along with a subgroup analysis for associated factors. The research identified ABO blood type as an independent prognostic factor in severe burn injuries. It was found that blood type O is associated with better OS, while blood type B is linked to lower OS (<i>p</i> = 0.001). Clinical variables such as acute kidney injury (AKI), sepsis, and other complications influenced the effect of ABO blood type on OS, according to our subgroup analysis. Our findings indicated that blood type B was an independent and significant predictor of OS in patients with severe burn injuries, likely due to differences in immune and coagulation responses. Although the study focused on the relationship between blood type and OS, it also highlighted the importance of other factors, such as patient comorbidities and treatment approaches.
DOI: 10.7931/sgnf-np74
title: Litter Decomposition in Ecosanctuaries
DOI: 10.6084/m9.figshare.30695059
title: Albumin–globulin ratio is a predictive biomarker of antitumour effect of immune checkpoint inhibitors in cancer patients

description: Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, yet the heterogeneity of treatment responses underscores the need for reliable prognostic biomarkers. The albumin-to-globulin ratio (AGR), an indicator of systemic inflammation and nutritional status, has emerged as a potential predictor of ICI outcomes. This study aimed to systematically evaluate the prognostic significance of AGR in patients receiving ICIs through a meta-analysis and to validate the findings in a single-centre cohort. A systematic literature search was conducted using PubMed, EMBASE, and the Cochrane Library to identify studies published prior to June 6, 2025. The primary endpoints were overall survival (OS), progression-free survival (PFS), and disease control rate (DCR). In addition, a retrospective analysis was performed on a cohort of 74 patients with renal cell carcinoma (RCC) treated with ICIs at our institution to assess the prognostic value of baseline AGR in relation to OS and PFS. Seven studies encompassing 1,460 patients were included in the meta-analysis. Higher pretreatment AGR was significantly associated with improved OS (HR = 0.44; 95% CI: 0.30–0.66; <i>p</i> &lt; 0.001), extended PFS (HR = 0.61; 95% CI: 0.53–0.71; <i>p</i> &lt; 0.001), and superior DCR (OR = 4.48; 95% CI: 2.58–7.77; <i>p</i> &lt; 0.001). Sensitivity analyses confirmed the robustness of these associations. In our institutional RCC cohort, elevated AGR was independently linked to prolonged OS (<i>p</i> = 0.017) and PFS (<i>p</i> = 0.030), consistent with findings from the pooled data. AGR is a simple, inexpensive, and non-invasive biomarker with significant prognostic value in patients undergoing ICI therapy. These findings support its potential role in guiding clinical decision-making and optimizing patient selection for immunotherapy.
DOI: 10.6084/m9.figshare.30695059.v1
title: Albumin–globulin ratio is a predictive biomarker of antitumour effect of immune checkpoint inhibitors in cancer patients

description: Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, yet the heterogeneity of treatment responses underscores the need for reliable prognostic biomarkers. The albumin-to-globulin ratio (AGR), an indicator of systemic inflammation and nutritional status, has emerged as a potential predictor of ICI outcomes. This study aimed to systematically evaluate the prognostic significance of AGR in patients receiving ICIs through a meta-analysis and to validate the findings in a single-centre cohort. A systematic literature search was conducted using PubMed, EMBASE, and the Cochrane Library to identify studies published prior to June 6, 2025. The primary endpoints were overall survival (OS), progression-free survival (PFS), and disease control rate (DCR). In addition, a retrospective analysis was performed on a cohort of 74 patients with renal cell carcinoma (RCC) treated with ICIs at our institution to assess the prognostic value of baseline AGR in relation to OS and PFS. Seven studies encompassing 1,460 patients were included in the meta-analysis. Higher pretreatment AGR was significantly associated with improved OS (HR = 0.44; 95% CI: 0.30–0.66; <i>p</i> &lt; 0.001), extended PFS (HR = 0.61; 95% CI: 0.53–0.71; <i>p</i> &lt; 0.001), and superior DCR (OR = 4.48; 95% CI: 2.58–7.77; <i>p</i> &lt; 0.001). Sensitivity analyses confirmed the robustness of these associations. In our institutional RCC cohort, elevated AGR was independently linked to prolonged OS (<i>p</i> = 0.017) and PFS (<i>p</i> = 0.030), consistent with findings from the pooled data. AGR is a simple, inexpensive, and non-invasive biomarker with significant prognostic value in patients undergoing ICI therapy. These findings support its potential role in guiding clinical decision-making and optimizing patient selection for immunotherapy.
DOI: 10.6084/m9.figshare.28616455
title: Exploring NamiRNA networks and time-series gene expression in osteogenic differentiation of adipose-derived stem cells

description: Adipose-derived stem cells (ADSCs) are a type of stem cell found in adipose tissue with the capacity to differentiate into multiple lineages, including osteoblasts. The differentiation of ADSCs into osteoblasts underlies osteogenic and pathological cellular basis in osteoporosis, bone damage and repair. Focused on ADSCs osteogenic differentiation, we conducted mRNA, microRNA expression and bioinformatics analysis, including gene differential expression, time series-based trend analysis, functional enrichment, and generates potential nuclear activating miRNAs (NamiRNA) regulatory network. The screened mRNAs in NamiRNA regulatory network were validated with correlation analysis. The NamiRNA Regulatory Network reveals 4 mRNAs (C12orf61, MIR31HG, NFE2L1, and PCYOX1L) significantly downregulated in differentiated group and may be associated with ADSCs stemness. Furthermore, the significantly upregulated 10 genes (ACTA2, TAGLN, LY6E, IFITM3, NGFRAP1, TCEAL4, ATP5C1, CAV1, RPSA, and KDELR3) were significantly enriched in osteogenic-related pathways, and negatively correlated with ADSCs cell stemness <i>in vitro</i>. These findings uncover potential genes related to ADSCs osteogenic differentiation, and provide theoretical basis for underlying ADSCs osteogenic differentiation and related diseases.
DOI: 10.6084/m9.figshare.28616455.v1
title: Exploring NamiRNA networks and time-series gene expression in osteogenic differentiation of adipose-derived stem cells

description: Adipose-derived stem cells (ADSCs) are a type of stem cell found in adipose tissue with the capacity to differentiate into multiple lineages, including osteoblasts. The differentiation of ADSCs into osteoblasts underlies osteogenic and pathological cellular basis in osteoporosis, bone damage and repair. Focused on ADSCs osteogenic differentiation, we conducted mRNA, microRNA expression and bioinformatics analysis, including gene differential expression, time series-based trend analysis, functional enrichment, and generates potential nuclear activating miRNAs (NamiRNA) regulatory network. The screened mRNAs in NamiRNA regulatory network were validated with correlation analysis. The NamiRNA Regulatory Network reveals 4 mRNAs (C12orf61, MIR31HG, NFE2L1, and PCYOX1L) significantly downregulated in differentiated group and may be associated with ADSCs stemness. Furthermore, the significantly upregulated 10 genes (ACTA2, TAGLN, LY6E, IFITM3, NGFRAP1, TCEAL4, ATP5C1, CAV1, RPSA, and KDELR3) were significantly enriched in osteogenic-related pathways, and negatively correlated with ADSCs cell stemness <i>in vitro</i>. These findings uncover potential genes related to ADSCs osteogenic differentiation, and provide theoretical basis for underlying ADSCs osteogenic differentiation and related diseases.
DOI: 10.6084/m9.figshare.30498670
title: Long-term healthcare use of COVID-19 cases in 2020: a two-year follow-up in Stockholm, Sweden

description: There is limited data on whether SARS-CoV-2 infections will result in increased long-term use of general healthcare, potentially impacting healthcare systems and management. Exploring this, we investigated the healthcare use of individuals with a SARS-CoV-2 infection in 2020 over a period of two years, using comprehensive medical records. We followed a cohort of 365,354 individuals in Stockholm, Sweden, who had been tested with SARS-CoV-2 serology in 2020, for healthcare use during 2021/22. SARS-CoV-2 seropositive and seronegative individuals were matched 1:1 on age, sex, 2019 healthcare use, and date of last serology, and compared on healthcare use during 2021/22 using registry linkages. Seropositive individuals were stratified on hospitalization for COVID-19 in 2020. Individuals were compared for total healthcare use, measured as incidence rate rations (IRR), and healthcare type usage-or-not per month, measured as a difference-in-differences regression. There were 272,918 seronegative and 73,814 seropositive subjects. Incidence rate ratios (IRRs) for primary healthcare use were 1.0, 1.16, and 0.98, for all, only hospitalized, and only non-hospitalized, seropositive individuals respectively. For outpatient specialist care IRRs were 0.96, 1.31, and 0.93. For inpatient care IRRs were 0.98, 1.19, and 0.95. Healthcare type usage-or-not per month showed no substantial differences, ranging from 0.01 to -0.01 in deviation. Increased healthcare use during follow-up was restricted to the seropositive individuals hospitalized for COVID-19 in 2020. There was no increase in healthcare use in the overall population from SARS-CoV-2 infections during 2020, suggesting there is no apparent need to adapt healthcare systems at scale for the COVID-19 aftermath.
DOI: 10.6084/m9.figshare.30498670.v1
title: Long-term healthcare use of COVID-19 cases in 2020: a two-year follow-up in Stockholm, Sweden

description: There is limited data on whether SARS-CoV-2 infections will result in increased long-term use of general healthcare, potentially impacting healthcare systems and management. Exploring this, we investigated the healthcare use of individuals with a SARS-CoV-2 infection in 2020 over a period of two years, using comprehensive medical records. We followed a cohort of 365,354 individuals in Stockholm, Sweden, who had been tested with SARS-CoV-2 serology in 2020, for healthcare use during 2021/22. SARS-CoV-2 seropositive and seronegative individuals were matched 1:1 on age, sex, 2019 healthcare use, and date of last serology, and compared on healthcare use during 2021/22 using registry linkages. Seropositive individuals were stratified on hospitalization for COVID-19 in 2020. Individuals were compared for total healthcare use, measured as incidence rate rations (IRR), and healthcare type usage-or-not per month, measured as a difference-in-differences regression. There were 272,918 seronegative and 73,814 seropositive subjects. Incidence rate ratios (IRRs) for primary healthcare use were 1.0, 1.16, and 0.98, for all, only hospitalized, and only non-hospitalized, seropositive individuals respectively. For outpatient specialist care IRRs were 0.96, 1.31, and 0.93. For inpatient care IRRs were 0.98, 1.19, and 0.95. Healthcare type usage-or-not per month showed no substantial differences, ranging from 0.01 to -0.01 in deviation. Increased healthcare use during follow-up was restricted to the seropositive individuals hospitalized for COVID-19 in 2020. There was no increase in healthcare use in the overall population from SARS-CoV-2 infections during 2020, suggesting there is no apparent need to adapt healthcare systems at scale for the COVID-19 aftermath.
DOI: 10.6084/m9.figshare.30284061
title: Urinary and circulatory levels of plasticizer metabolites and their associations with renal function: a cross-sectional analysis of the NHANES cohort

description: Plasticizers used in consumer products raise concerns for nephrotoxicity; while DEHP is well characterized, evidence for DEHTP and DiNP—particularly their metabolites—remains limited. We examined associations of five urinary metabolites—MEHHP/MECPP (DEHP), MEHHTP/MECPTP (DEHTP), and MONP (DiNP)—with renal endpoints in a nationally representative adult sample. We analyzed 2,229 adults from NHANES 2015–2018 using multivariable linear and restricted cubic spline models for eGFR, and evaluated combined-exposure effects with WQS and BKMR; analyses were repeated with UACR as a secondary outcome. Higher MECPP and MEHHP were associated with lower eGFR, whereas positive associations for MECPTP and MEHHTP may reflect early glomerular hyperfiltration rather than benefit. As a secondary endpoint, UACR indicated early injury: MECPP increased UACR (<i>p</i> &lt; 0.001) and MONP decreased UACR (<i>p</i> = 0.002), with mild nonlinearity. Combined-exposure models prioritized DEHP/DEHTP metabolites, with MECPTP contributing most. Urinary plasticizer metabolites are linked to altered renal endpoints. Heterogeneous exposure–response patterns support complementary outcomes and mixture methods; longitudinal and mechanistic studies are needed to clarify causality and inform risk management for emerging plasticizers.
DOI: 10.6084/m9.figshare.30284061.v1
title: Urinary and circulatory levels of plasticizer metabolites and their associations with renal function: a cross-sectional analysis of the NHANES cohort

description: Plasticizers used in consumer products raise concerns for nephrotoxicity; while DEHP is well characterized, evidence for DEHTP and DiNP—particularly their metabolites—remains limited. We examined associations of five urinary metabolites—MEHHP/MECPP (DEHP), MEHHTP/MECPTP (DEHTP), and MONP (DiNP)—with renal endpoints in a nationally representative adult sample. We analyzed 2,229 adults from NHANES 2015–2018 using multivariable linear and restricted cubic spline models for eGFR, and evaluated combined-exposure effects with WQS and BKMR; analyses were repeated with UACR as a secondary outcome. Higher MECPP and MEHHP were associated with lower eGFR, whereas positive associations for MECPTP and MEHHTP may reflect early glomerular hyperfiltration rather than benefit. As a secondary endpoint, UACR indicated early injury: MECPP increased UACR (<i>p</i> &lt; 0.001) and MONP decreased UACR (<i>p</i> = 0.002), with mild nonlinearity. Combined-exposure models prioritized DEHP/DEHTP metabolites, with MECPTP contributing most. Urinary plasticizer metabolites are linked to altered renal endpoints. Heterogeneous exposure–response patterns support complementary outcomes and mixture methods; longitudinal and mechanistic studies are needed to clarify causality and inform risk management for emerging plasticizers.